Why the study?
Does continued use of ARBs reduce adverse cardiovascular and renal outcomes compared to CCBs in older adults on sustained antihypertensive therapy?
Population
59,558 older adults receiving sustained antihypertensive therapy who had continuously received either ARBs…
Comparison
Continued use of angiotensin receptor blockers vs Continued use of calcium channel blockers (CCBs)
Design
Cohort
Follow-up
median 4.75 years
Key result
In a 24-month landmark sensitivity analysis, continued use of ARBs was associated with a lower 5-year risk of heart failure hospitalization compared to CCBs (HR 0.885, 95% CI 0.835-0.939).
Authors
Loading...
May guide ARB vs CCB selection in older adults on long-term therapy; leaves open need for RCTs to confirm outcomes.
Cohort (n=59,558)
Yes
Does continued use of ARBs reduce adverse cardiovascular and renal outcomes compared to CCBs in older adults on sustained antihypertensive therapy?
In older adults on long-term antihypertensive therapy, continued ARB use is associated with lower risks of heart failure hospitalization and ESRD compared to CCBs, despite similar blood pressure control.
Noma et al. (2026) conducted a cohort in Hypertension (n=59,558). Angiotensin receptor blockers (ARBs) vs. Calcium channel blockers (CCBs) was evaluated. In a 24-month landmark sensitivity analysis, continued use of ARBs was associated with a lower 5-year risk of heart failure hospitalization compared to CCBs (HR 0.885, 95% CI 0.835-0.939).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: